SAN FRANCISCO–(COMMERCIAL WIRE)–viz.aithe leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with illuminate, inc., an industry leader in the development of proprietary natural language processing (NLP) and artificial intelligence software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and facilitates follow-up surveillance for a variety of diseases. This partnership will enable healthcare providers to make timely and critical decisions for aortic aneurysm patients while improving compliance with pre- and post-surgical surveillance programs.
“Aortic aneurysm is often called a silent killer with few symptoms before it’s too late,” said Jayme Strauss, Viz.ai’s clinical director. “We are excited to collaborate with Illuminate, harnessing the power of AI and NLP to extract insights from EMR data, radiology reports, and imaging studies. This partnership will improve the standard of care for these patients and help healthcare providers coordinate and deliver care at the right time.”
Aortic aneurysms often will not cause overt symptoms before a life-threatening rupture occurs, so early detection and management is critical. Illuminate’s NLP capability is a complement to Viz.ai’s growing platform, which will now offer healthcare systems a comprehensive solution to detect more suspicious aortic aneurysms earlier and ensure patients have access to life-saving treatments. lives or the surveillance they need through cross-functions. care teams.
“Aortic screening and surveillance programs are essential to ensure that aortic aneurysm patients are detected earlier so they receive the care and follow-up they need. Unfortunately, we have shown that patients often fall through the cracks in the care pathway,” said Dr. Steven Okuhn, Illuminate’s chief medical officer and a vascular surgeon at the San Francisco VA Medical Center. “This unique offering will help improve aortic aneurysm detection and patient workflow by combining natural language processing and image-based artificial intelligence. I am incredibly excited about this clear advance in the care of the aortic patient.”
“We are pleased to partner with viz.ai to provide end-to-end workflow, including follow-up surveillance and disease management, by combining our best-in-class technologies,” said Matt McLenon, CEO of Illuminate. “This will not only help increase surveillance and compliance and improve patient care, but will also enable faster enrollment of patients for clinical research studies.”
About Viz.ai, Inc.
Viz.ai is pioneering the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives in more than 1,200 hospitals and healthcare systems in the US and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, optimizes care pathways, and helps improve outcomes. Backed by clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit namely, oh.
About Illuminate, Inc.
Illuminate is the industry leader in patient discovery, tracking and management. By combining world-class NLP and AI with integrated clinical workflows, the Illuminate Platform enables organizations to deliver the highest quality care throughout the patient journey. Illuminate’s mission is to ensure that every patient is seen by the right care team at the right time.